The global pharmaceutical industry experienced a 1% decline in patent filings in Q3 2023 compared with the previous quarter. The total number of grants dropped by 8%, resulting in overall patent publications decreasing by 1.9%, according to GlobalData’s Patent Analytics. GlobalData’s databook Pharma: Patents Trends Q3 2023 offers comprehensive insights into patenting trends, major players’ strategies, and geographical focus in the sector over the last three years. Buy the databook here.

Smarter leaders trust GlobalData


Data Insights Pharma: Patents Trends Q3 2023

Buy the Databook

Data Insights

The gold standard of business intelligence.

Find out more

Notably, the number of patent applications in the pharmaceutical industry was 58,841 in Q3 2023, versus 59,991 in the prior quarter. Filings were down 14% year-on-year and decrease 1% quarter-on-quarter. This compares to a 14% year-on-year decrease in patent grants and 1% decline in quarter-on-quarter.

The top five companies accounted for 3% of patenting activity

Analysis of patenting activity by companies shows that the largest number of patents filed over the last quarter was by F. Hoffmann-La Roche with 520, followed by Zhejiang University with 375 and Johnson & Johnson with 318.

Patenting activity was driven by China with a 38% share of total patent filings

The largest share of patent filings in the pharmaceutical industry in Q3 2023 was in China with 38%, followed by the US (14%) and Japan (7%). The share represented by China was 7% higher than the 31% share it accounted for in Q2 2023.

For further understanding of GlobalData's Pharma: Patents Trends Q3 2023, buy the databook here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.